Skip to main content
. 2021 May 10;6(3):100150. doi: 10.1016/j.esmoop.2021.100150

Figure 2.

Figure 2

Kaplan–Meier plots for overall survival (A) in all patients treated with IT therapy; (B) according to BC subtype (HR+/HER2− versus HER2+ versus TN, log-rank P < 0.0001); (C) according to IT agent (methotrexate versus cytarabine or thiotepa, log-rank P = 0.047).

BC, breast cancer; CI, confidence interval; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IT, intrathecal; OS, overall survival; TN, triple negative.